Table 3 Summary of studies reporting an adjusted survival analysis for mortality. Included studies report adjusted analyses and are subdivided according to population type (D-KD, CKDG3−5, KTR and HF). Where studies describe the same cohort of patients (see further detail in Supplementary Table 1) they are sequentially numbered by cohort number (15 studies describe 6 separate cohorts of patients: 1 HF and 5 D-KD). Estimates of effect are summarised for each study outcome including – all-cause mortality (ACM), cardiovascular mortality (CVM), cardiovascular events (CVE) or composite outcomes. If the estimate of effect is statistically significant then this is highlighted with as an asterisk (*). One study reported an implausible follow up period (designated ^ in the table). Covariates included within the adjusted analysis are marked a “X” in the covariate matrix. Abbreviations for bioimpedance defined muscle mass (BI-MM) measures include: body cell mass (BCM), bioimpedance vector analysis (BIVA), bioimpedance spectroscopy estimated muscle mass (BIS-MM), fat free mass (FFM), impedance ratio (ImpRatio), intracellular water (ICW), lean body mass (LBM), lean tissue mass (LTM), lean tissue mass used in sarcopaenia diagnosis (LTM sarco), phase angle (PA) and skeletal muscle mass index (SMMI). Additional abbreviations used in this table include: BMI – body mass index, ComorbS – comorbidity score, CPHM – Cox proportional hazards model, CRP – C-reactive protein, CVD – cardiovascular disease, DM – diabetes mellitus, eGFR – estimated glomerular filtration rate, HD – haemodialysis, Hb – haemoglobin, HTN – hypertension, InflammD – inflammatory diseases, KRT – kidney replacement therapy, Kt/V – dialysis dose, PD – peritoneal dialysis. RKF – residual kidney function, sAlb – serum albumin and Tx – transplant.
